@FierceMedDev: Sign up for our new publication, FierceDiagnostics, launching with its first weekly newsletter this Wednesday. Sign up | Follow @FierceMedDev
@DamianFierce: CROs are dishing out more and more bonuses to quell sky-high turnover rates, according to a study. Report | Follow @DamianFierce
@MarkHFierce: Thermo Fisher is rolling out a major scholarship program for science/math students at elite universities. Smart. Release | Follow @MarkHFierce
@MichaelGFierce: Zimmer lands FDA clearance for 3-D surgical system. Article | Follow @MichaelGFierce
> Medtronic ($MDT) vice president H. James Dallas has unloaded 32,332 shares of stock on the open market. Story
> Thermo Fisher Scientific ($TMO) is launching a major scholarship program for students pursuing degrees in science, technology, engineering and math at 5 major universities around the world, including MIT. Item
> A Theragenics-sponsored survey determined that a large majority of men may think they're getting a PSA test as part of overall lab work, even though guidelines recommend against prostate cancer screening for healthy men. Item
> The Society of Laparoendoscopic Surgeons named a surgical closure device made by Suture Ease in Utah as one of its 2013 Innovations of the Year. Item
> Teleflex ($TFX) plans to promote its anesthesia and pain management devices during the ESRA Congress in Glasgow, U.K., from Sept. 4-7, 2013. Item
Biotech News
@FierceBiotech: Rigel shares slide after another drug flops in PhII asthma study. Story | Follow @FierceBiotech
@JohnCFierce: Two years ago Rigel was celebrating when Pfizer turned over R343. Now enthusiasm likely dimmed as top 2 drugs are under a dark cloud. Story | Follow @JohnCFierce
@EmilyMFierce: High copper levels implicated in #Alzheimer's disease. Story | Follow @EmilyMFierce
> Argos turns to unusual players for $42.5M needed to fund PhIII cancer study. News
> AstraZeneca forges $500M cancer-combo tech buyout for MedImmune. More
> Amgen bags Onyx Pharma in $10.4B buyout deal. Story
Pharma News
@FiercePharma: Japan's budget-minded PM wants to open universal health system to more add-on treatments. Could boost cancer meds. Article | Follow @FiercePharma
@EricPFierce: Australia to track Yervoy patients to see if it's worth the $110K price. More | Follow @EricPFierce
@CarlyHFierce: Ex-Novartis chair Vasella considers his results worth the once-approved $78M payout--will make $5.2M instead. Story | Follow @CarlyHFierce
> Australia to track Yervoy patients to see if it's worth the $110K price. News
> Sanofi eyes superiority claim for Fluzone High-Dose after trial boost. More
CRO News
> U.K. outfit bets on early-phase outsourcing. News
> CRO Psi jumps into India. More
> Vince & Associates eyes gastro trials with expansion. Article
> Study: CROs dishing out bonuses to halt high turnover. Story
> Icon dives into adaptive trial monitoring. News
Biotech IT News
> Capgemini taps Amazon cloud for Big Data analytics. Story
> Harvard-MIT collaboration adds Lego-like genome analysis tool. Article
> Google bolsters security of cloud data storage service. More
> FDA pilot project ups benefits of IT supply chain investments. News
> EMA to start accepting digital signatures next month. Story